Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 730357 (Bevurogant) Bioavailability with Itraconazole
NCT03782987Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bevurogant in plaque psoriasis (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 730357 in Plasma and Maximum Measured Concentration of BI 730357 in Plasma. Started Jan 2019; status: completed.
02
Drugs
bevurogant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03782987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782987.